TPST TEMPEST THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TEMPEST THERAPEUTICS INC reported revenue of n/a, net income of −$5.24M and diluted EPS of −$0.34; for the fiscal year ended December 2025 revenue was n/a.
TPST annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$26.6M, net income −$26.3M (margin n/a), EPS −$6.33
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$42.0M, net income −$41.8M (margin n/a), EPS −$19.50
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$29.2M, net income −$29.5M (margin n/a), EPS −$1.91
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$34.6M, net income −$35.7M (margin n/a), EPS −$3.09
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$27.0M, net income −$28.3M (margin n/a), EPS −$7.47
TPST quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.24M, EPS −$0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$27.7M, EPS −$2.53
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.02M, EPS −$0.31
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.51M, EPS −$0.79
- Quarter ended Jun 30, 2025: revenue n/a, net income −$7.87M, EPS −$2.07
- Quarter ended Mar 31, 2025: revenue n/a, net income −$10.9M, EPS −$3.16
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$13.8M, EPS −$4.04
- Quarter ended Sep 30, 2024: revenue n/a, net income −$10.6M, EPS −$5.32
- Quarter ended Jun 30, 2024: revenue n/a, net income −$9.57M, EPS −$5.52
- Quarter ended Mar 31, 2024: revenue n/a, net income −$7.90M, EPS −$4.62
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.49M, EPS −$0.34
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.79M, EPS −$0.48
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.58M, EPS −$0.54
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.64M, EPS −$0.55
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.10M, EPS −$0.46
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.95M, EPS −$0.66
- Quarter ended Jun 30, 2022: revenue n/a, net income −$9.17M, EPS −$0.79
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.49M, EPS −$1.18
- Quarter ended Dec 31, 2021: revenue n/a, net income −$28.3M, EPS $11.92
- Quarter ended Sep 30, 2021: revenue n/a, net income −$8.11M, EPS −$1.21
TPST cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$26.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$33.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$27.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$31.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$26.0M, share buybacks n/a
TPST balance sheet
- Jun 30, 2026: cash $779K, total assets $9.63M, total liabilities $10.7M, shareholders' equity −$1.09M
- Mar 31, 2026: cash $1.81M, total assets $10.7M, total liabilities $9.93M, shareholders' equity $822K
- Dec 31, 2025: cash $7.71M, total assets $16.9M, total liabilities $10.3M, shareholders' equity $6.67M
- Sep 30, 2025: cash $7.51M, total assets $17.1M, total liabilities $10.8M, shareholders' equity $6.35M
- Jun 30, 2025: cash $14.3M, total assets $24.5M, total liabilities $14.7M, shareholders' equity $9.78M
- Mar 31, 2025: cash $21.5M, total assets $32.2M, total liabilities $21.0M, shareholders' equity $11.1M
- Dec 31, 2024: cash $30.3M, total assets $41.5M, total liabilities $22.4M, shareholders' equity $19.1M, long-term debt $0
- Sep 30, 2024: cash $22.1M, total assets $33.8M, total liabilities $22.4M, shareholders' equity $11.5M, long-term debt $0
Is TPST profitable?
No. TEMPEST THERAPEUTICS INC lost $40.5M over the last four quarters.
What is TPST's EPS?
Diluted earnings per share over the last four quarters were −$3.97; −$0.34 in the latest quarter.